Respiratory tract infections, including atypical pneumonia, ENT infections (tonsillitis, otitis, sinusitis), purulent inflammatory diseases of the skin and its appendages, erythrasma, diphtheria, gonorrhea, syphilis, listeriosis, Legionnaires ‘ disease, infections in dentistry and ophthalmology, infections caused by microorganisms resistant to beta-lactam antibiotics, penicillin, tetracycline, levomycetin, chloramphenicol, streptomycin.
active substance: erythromycin;
1 tablet contains erythromycin – 100 mg;
excipients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate.
Eritromicin Dosage form
Basic physical and chemical properties: tablets of a round shape, white or almost white or white with a yellowish tinge, beveled. Subtle inclusions are allowed.
Antibacterial agents for systemic use. Macrolides. Erythromycin. ATX code J01F A01.
Erythromycin is a macrolide antibiotic with bacteriostatic action. In high concentrations and in relation to highly sensitive microorganisms, it can have a bactericidal effect. Penetrates through the cell membrane of bacteria and reversibly binds to the 50S subunit of bacterial ribosomes; inhibits the translocation of peptides from the acceptor region of the ribosome to the donor one, preventing further protein synthesis.
Active against gram-positive bacteria: Streptococcus pyogenes, Streptococcus viridans, Streptococcus pneumoniae, Staphylococcus aureus, Corynebacterium diphtheriae, Corynebacterium minutissimum, Listeria monocytogenes; gram-negative bacteria: Bordetella pertussis, Legionella pneumophila, some strains of Haemophilus influenzae, Mycoplasma pneumoniae, as well as in relation to Entaemoeba hystolitica, Chlamydia trachomatis, Treponema pallidum.
Gram-negative bacilli are resistant to erythromycin: intestinal, Pseudomonas aeruginosa, as well as Shigella, Salmonella.
It is absorbed in the digestive tract, while the rate of absorption depends on the individual characteristics of the organism. Bioavailability is 30-65%. The maximum concentration in the blood is reached 2 hours after ingestion. It is distributed in most tissues and body fluids, penetrates the placental barrier and into breast milk.
Plasma protein binding is 70-90%. It is metabolized in the liver, partly with the formation of inactive metabolites. A significant part of erythromycin is excreted in the bile and only 2-5% is excreted unchanged in the urine. The half-life is 1.4-2 hours with normal renal function.
Respiratory tract infections, including SARS, ENT infections (tonsillitis, otitis media, sinusitis), purulent-inflammatory diseases of the skin and its appendages, erythrasma, diphtheria, gonorrhea, syphilis, listeriosis, Legionnaires’ disease, infections in dentistry and ophthalmology, infections caused by microorganisms resistant to beta-lactam antibiotics, penicillin, tetracycline, chloramphenicol, streptomycin.
Hypersensitivity to erythromycin or to any component of the drug, to macrolides;
Severe liver failure;
The patient has a history of lengthening the QT interval (congenital or acquired, documented) or ventricular arrhythmias, including “torsade de pointes”;
Electrolyte imbalance (hypokalemia, hypomagnesemia – due to the risk of lengthening the QT interval);
Simultaneous use with simvastatin, domperidone, tolterodine, mizolastine, amisulpride, terfenadine, astemizole, pimozide or cisapride, ergotamine and dihydroergotamine.